PRb/E2F-1-mediated caspase-dependent induction of Noxa amplifies the apoptotic effects of the Bcl-2/Bcl-xL inhibitor ABT-737

Cell Death and Differentiation

Volumn 20, Issue 5, 2013, Pages 755-764

  Bertin Ciftci, J ^a   Barre B ^b   Le Pen, J ^a   Maillet, L ^a   Couriaud, C ^a   Juin, P ^a,c   Braun, F ^a  

^a UNIVERSITÉ DE NANTES   (France)

^b UNIVERSITÉ D'ANGERS   (France)

^c CENTRE RENÉ GAUDUCHEAU   (France)

Author keywords

apoptosis; Bcl 2 family; caspase; Noxa; pRb E2F 1

Indexed keywords

4 [4 (4' CHLORO 2 BIPHENYLYLMETHYL) 1 PIPERAZINYL] N [4 [3 DIMETHYLAMINO 1 (PHENYLTHIOMETHYL)PROPYLAMINO] 3 NITROBENZENESULFONYL]BENZAMIDE; CASPASE; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1; PROTEIN NOXA; RETINOBLASTOMA PROTEIN; RNA; TRANSCRIPTION FACTOR E2F1;

APOPTOSIS; ARTICLE; CELL DEATH; CONTROLLED STUDY; ENZYME ACTIVITY; GLIOMA CELL; MITOCHONDRION; PRIORITY JOURNAL; PROMOTER REGION; RNA INTERFERENCE;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BCL-2-ASSOCIATED X PROTEIN; BCL-X PROTEIN; BIPHENYL COMPOUNDS; BREAST NEOPLASMS; CASPASES; CELL LINE, TUMOR; DNA-BINDING PROTEINS; E2F1 TRANSCRIPTION FACTOR; FEMALE; HUMANS; MITOCHONDRIA; NITROPHENOLS; NUCLEAR PROTEINS; PIPERAZINES; PROMOTER REGIONS, GENETIC; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RETINOBLASTOMA PROTEIN; RNA INTERFERENCE; RNA, SMALL INTERFERING; SULFONAMIDES; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEINS;

EID: 84877577877     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2013.6     Document Type: Article

References (49)

1. Adams JM, Cory S. The Bcl-2 apoptotic switch in cancer development and therapy. Oncogene 2007; 26: 1324-1337.
2. Lalier L, Cartron P-F, Juin P, Nedelkina S, Manon S, Bechinger B et al. Bax activation and mitochondrial insertion during apoptosis. Apoptosis 2007; 12: 887-896.
3. Chipuk JE, Moldoveanu T, Llambi F, Parsons MJ, Green DR. The BCL-2 family reunion. Mol Cell 2010; 37: 299-310.
4. Kelly PN, Strasser A. The role of Bcl-2 and its pro-survival relatives in tumourigenesis and cancer therapy. Cell Death Differ 2011; 18: 1414-1424.
5. Chonghaile TN, Letai A. Mimicking the BH3 domain to kill cancer cells. Oncogene 2009; 27: S149-S157.
6. Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI, Hinds MG et al. Differential targeting of prosurvival Bcl-2 proteins by their BH3-Only ligands allows complementary apoptotic function. Mol Cell 2005; 17: 393-403.
7. Shamas-Din A, Brahmbhatt H, Leber B, Andrews DW. BH3-only proteins: orchestrators of apoptosis. Biochim Biophys Acta 2011; 1813: 508-520.
8. Aranovich A, Liu Q, Collins T, Geng F, Dixit S, Leber B et al. Differences in the mechanisms of proapoptotic BH3 proteins binding to Bcl-XL and Bcl-2 quantified in live MCF-7 cells. Mol Cell 2012; 45: 754-763.
9. Oltersdorf T, Elmore SW, Shoemaker AR, Armstrong RC, Augeri DJ, Belli BA et al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005; 435: 677-681.
10. Del Gaizo Moore V, Brown JR, Certo M, Love TM, Novina CD, Letai A. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J Clin Invest 2007; 117: 112-121.
11. Gallenne T, Gautier F, Oliver L, Hervouet E, Noel B, Hickman JA et al. Bax activation by the BH3-only protein Puma promotes cell dependence on antiapoptotic Bcl-2 family members. J Cell Biol 2009; 185: 279-290.
12. Gautier F, Guillemin Y, Cartron PF, Gallenne T, Cauquil N, Le Diguarher T et al. Bax activation by engagement with, then release from, the BH3 binding site of Bcl-xL. Mol Cell Biol 2011; 31: 832-844.
13. van Delft MF, Wei AH, Mason KD, Vandenberg CJ, Chen L, Czabotar PE et al. The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. Cancer Cell 2006; 10: 389-399.
14. Tagscherer KE, Fassl A, Campos B, Farhadi M, Kraemer A, Bock BC et al. Apoptosisbased treatment of glioblastomas with ABT-737, a novel small molecule inhibitor of Bcl-2 family proteins. Oncogene 2008; 27: 6646-6656.
15. Okumura K, Huang S, Sinicrope FA. Induction of Noxa sensitizes human colorectal cancer cells expressing Mcl-1 to the small-molecule Bcl-2/Bcl-xL inhibitor, ABT-737. Clin Cancer Res 2008; 14: 8132-8142.
16. Zall H, Weber A, Besch R, Zantl N, Häcker G. Chemotherapeutic drugs sensitize human renal cell carcinoma cells to ABT-737 by a mechanism involving the Noxa-dependent inactivation of Mcl-1 or A1. Mol Cancer 2010; 9: 164.
17. Zhang L, Lopez H, George NM, Liu X, Pang X, Luo X. Selective involvement of BH3-only proteins and differential targets of Noxa in diverse apoptotic pathways. Cell Death Differ 2011; 18: 864-873.
18. Quinn BA, Dash R, Azab B, Sarkar S, Das SK, Kumar S et al. Targeting Mcl-1 for the therapy of cancer. Expert Opin Investig Drugs 2011; 10: 1397-1411.
19. Lakhani SA, Masud A, Kuida K, Porter GA Jr, Booth CJ, Mehal WZ et al. Caspases 3 and 7: key mediators of mitochondrial events of apoptosis. Science 2006; 311: 847-851.
20. Tait SWG, Parsons MJ, Llambi F, Bouchier-Hayes L, Connell S, Muñoz-Pinedo C et al. Resistance to caspase-independent cell death requires persistence of intact mitochondria. Dev Cell 2010; 18: 802-813.
21. Llambi F, Moldoveanu T, Tait SWG, Bouchier-Hayes L, Temirov J, McCormick LL et al. A unified model of mammalian BCL-2 protein family interactions at the mitochondria. Mol Cell 2011; 44: 517-531.
22. Buron N, Porceddu M, Brabant M, Desgué D, Racoeur C, Lassalle M et al. Use of human cancer cell lines mitochondria to explore the mechanisms of BH3 peptides and ABT-737-induced mitochondrial membrane permeabilization. PLoS One 2010; 5: e9924.
23. Song JH, Kandasamy K, Kraft AS. ABT-737 induces expression of the death receptor 5 and sensitizes human cancer cells to TRAIL-induced apoptosis. J Biol Chem 2008; 283: 25003-25013.
24. Song JH, Kandasamy K, Zemskova M, Lin Y-W, Kraft AS. The BH3 mimetic ABT-737 induces cancer cell senescence. Cancer Res 2011; 71: 506-515.
25. Stevens C, La Thangue NB. The emerging role of E2F-1 in the DNA damage response and checkpoint control. DNA Repair (Amst) 2004; 3: 1071-1079.
26. Polager S, Ginsberg D. p53 and E2f: partners in life and death. Nat Rev Cancer 2009; 9: 738-748.
27. Polager S, Ginsberg D. E2F-at the crossroads of life and death. Trends Cell Biol 2008; 18: 528-535.
28. Iaquinta PJ, Lees JA. Life and death decisions by the E2F transcription factors. Curr Opin Cell Biol 2007; 19: 649-657.
29. Stiewe T, Pützer BM. Role of the p53-homologue p73 in E2F1-induced apoptosis. Nat Genet 2000; 26: 464-469.
30. Hershko T, Ginsberg D. Up-regulation of Bcl-2 homology 3 (BH3)-only proteins by E2F1 mediates apoptosis. J Biol Chem 2004; 279: 8627-8634.
31. Zhao Y, Tan J, Zhuang L, Jiang X, Liu ET, Yu Q. Inhibitors of histone deacetylases target the Rb-E2F1 pathway for apoptosis induction through activation of proapoptotic protein Bim. Proc Natl Acad Sci USA 2005; 102: 16090-16095.
32. Hao H, Dong Y, Bowling MT, Gomez-Gutierrez JG, Zhou HS, McMasters KM. E2F-1 induces melanoma cell apoptosis via PUMA up-regulation and Bax translocation. BMC Cancer 2007; 7: 24.
33. Ambrosini G, Sambol EB, Carvajal D, Vassilev LT, Singer S, Schwartz GK. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1. Oncogene 2007; 26: 3473-3481.
34. Peirce SK, Findley HW. The MDM2 antagonist nutlin-3 sensitizes p53-null neuroblastoma cells to doxorubicin via E2F1 and TAp73. Int J Oncol 2009; 34: 1395-1402.
35. An B, Dou QP. Cleavage of retinoblastoma protein during apoptosis: an interleukin 1 beta-converting enzyme-like protease as candidate. Cancer Res 1996; 56: 438-442.
36. Boutillier AL, Trinh E, Loeffler JP. Caspase-dependent cleavage of the retinoblastoma protein is an early step in neuronal apoptosis. Oncogene 2000; 19: 2171-2178.
37. Fattman CL, Delach SM, Dou QP, Johnson DE. Sequential two-step cleavage of the retinoblastoma protein by caspase-3/-7 during etoposide-induced apoptosis. Oncogene 2001; 20: 2918-2926.
38. Dick FA. Structure-function analysis of the retinoblastoma tumor suppressor protein-is the whole a sum of its parts? Cell Div 2007; 2: 26.
39. Cecchini MJ, Dick FA. The biochemical basis of CDK phosphorylation- independent regulation of E2F1 by the retinoblastoma protein. Biochem J 2011; 434: 297-308.
40. Julian LM, Palander O, Seifried LA, Foster JEG, Dick FA. Characterization of an E2F1-specific binding domain in pRB and its implications for apoptotic regulation. Oncogene 2008; 27: 1572-1579.
41. Ianari A, Natale T, Calo E, Ferretti E, Alesse E, Screpanti I et al. Proapoptotic function of the retinoblastoma tumor suppressor protein. Cancer Cell 2009; 15: 184-194.
42. Albershardt TC, Salerni BL, Soderquist RS, Bates DJP, Pletnev AA, Kisselev AF et al. Multiple BH3 mimetics antagonize anti-apoptotic MCL1 by inducing the endoplasmic reticulum stress response and up-regulating BH3-only protein NOXA. J Biol Chem 2011; 28: 24882-24895.
43. Katsuda K, Kataoka M, Uno F, Murakami T, Kondo T, Roth JA et al. Activation of caspase-3 and cleavage of Rb are associated with p16-mediated apoptosis in human non-small cell lung cancer cells. Oncogene 2002; 21: 2108-2113.
44. Sellers WR, Novitch BG, Miyake S, Heith A, Otterson GA, Kaye FJ et al. Stable binding to E2F is not required for the retinoblastoma protein to activate transcription, promote differentiation, and suppress tumor cell growth. Genes Dev 1998; 12: 95-106.
45. Gjoerup O, Zaveri D, Roberts TM. Induction of p53-independent apoptosis by simian virus 40 small t antigen. J Virol 2001; 75: 9142-9155.
46. Helin K, Wu CL, Fattaey AR, Lees JA, Dynlacht BD, Ngwu C et al. Heterodimerization of the transcription factors E2F-1 and DP-1 leads to cooperative trans-activation. Genes Dev 1993; 7:1850-1861.
47. Pear WS, Miller JP, Xu L, Pui JC, Soffer B, Quackenbush RC et al. Efficient and rapid induction of a chronic myelogenous leukemia-like myeloproliferative disease in mice receiving P210 bcr/abl-transduced bone marrow. Blood 1998; 92: 3780-3792.
48. Braun F, Bertin-Ciftci J, Gallouet A-S, Millour J, Juin P. Serum-nutrient starvation induces cell death mediated by Bax and Puma that is counteracted by p21 and unmasked by Bcl-xL inhibition. PLoS One 2011; 6: e23577.
49. Barré B, Perkins ND. The Skp2 promoter integrates signaling through the NF-kappaB, p53, and Akt/GSK3beta pathways to regulate autophagy and apoptosis. Mol Cell 2010; 38: 524-538.